La Jolla Pharmaceutical Company is a dedicated brand that focuses on the commercialization of innovative therapies for patients suffering from life-threatening diseases. They offer two FDA-approved products: GIAPREZA™ and XERAVA™. GIAPREZA™ is a vasoconstrictor that increases blood pressure in adults with septic or other distributive shock, while XERAVA™ is used to treat complicated intra-abdominal infections.

The company is led by a team of experienced professionals. Larry Edwards serves as the President and Chief Executive Officer, bringing years of expertise in the pharmaceutical industry. Dr.

Tony Hodges is the Chief Medical Officer, responsible for overseeing medical operations. Luke Seikkula, the Senior Vice President of Pharmaceutical Operations, and Steven Ferris, the Vice President of Quality Assurance, play crucial roles in ensuring the smooth functioning of the company's operations. Paula Rusu, the Vice President of Operations, brings her vast experience in commercial operations to the team.

La Jolla Pharmaceutical Company is committed to improving patient outcomes through their innovative therapies, backed by a strong and experienced management team